SYRE
Spyre Therapeutics, Inc. (SYRE) ESG Analysis Analysis (2026)
Environmental
SYRE’s R&D intensity at 2.38% of revenue suggests some product or process innovation, but peers with heavier climate or resource disclosure may show clearer environmental leadership.
Zero reported debt-to-equity reduces balance-sheet pressure that can otherwise constrain environmental capex, though this metric is less directly informative than emissions or energy data versus peers.
The absence of provided emissions, water, or waste metrics limits evidence of environmental outperformance, leaving SYRE’s positioning closer to peer-average disclosure quality than a clear leader.
With no disclosed environmental incident or compliance data in the supplied metrics, the company avoids an obvious peer disadvantage, but the dataset is too thin to support a stronger score.
Social
Stock-based compensation equal to 50.5% of revenue can align employees with long-term value creation, but it may also indicate a compensation structure heavier than many peers.
The provided metrics do not include workforce safety, turnover, diversity, or customer-impact indicators, so SYRE cannot be credited for stronger social management versus peers.
R&D spending can support product quality and responsible innovation, yet the available data do not show whether this translates into superior employee or stakeholder outcomes.
Because the dataset lacks controversy, labor, or community metrics, SYRE appears neither clearly advantaged nor structurally weaker than peers on social factors.
Governance
Zero debt-to-equity indicates conservative capital structure and lower creditor pressure, which generally supports governance flexibility relative to more leveraged peers.
Net debt to EBITDA of 0.87 suggests manageable leverage, reducing refinancing risk and limiting governance stress compared with highly indebted peers.
Stock-based compensation at 50.5% of revenue is a governance concern because it can dilute shareholders and signal weaker pay discipline than better-aligned peers.
The absence of board, audit, ownership, and controversy data prevents a stronger governance assessment, so SYRE remains moderately positioned rather than clearly superior.
Overall Score
SYRE’s ESG positioning is moderate versus peers because conservative leverage supports governance, but the limited disclosure set prevents evidence of broad environmental or social leadership.
Score Driver: Limited ESG Disclosure Prevents A Stronger Peer-Relative Assessment.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Spyre Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

